THE SHARE: Change: -0.01 SEK (-5.15%) / Price: 0.11 SEK / Jan 2, 2026, 2:42 pm (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

Press Releases

  • 27 Aug, 2015
    Delårsrapport januari – juni 2015
  • 26 Jun, 2015
    SpagoPix produktpatent godkänt i USA
  • 6 May, 2015
    Kommuniké från årsstämma i Spago Nanomedical AB
  • 5 May, 2015
    Årsstämma 2015
  • 29 Apr, 2015
    Delårsrapport januari – mars 2015
  • 14 Apr, 2015
    Spago Nanomedical AB årsredovisning 2014
  • 27 Mar, 2015
    Kallelse till årsstämma i Spago Nanomedical AB (publ)
  • 20 Feb, 2015
    Bokslutskommuniké januari – december 2014
  • 14 Nov, 2014
    Delårsrapport januari – september 2014
  • 9 Oct, 2014
    Study with Spago Pix contrast agent published in PLOS ONE
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 21
  • Previous
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications